M. Agha

发表

Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature

A. Raptis, A. Im, M. Boyiadzis, 2016, Acta Haematologica.

CD-19 CART therapy and orthostatic hypotension: a single center retrospective cohort study

Joshua Levenson, K. Dorritie, Ashish Patel, 2022, Cardio-Oncology.

Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature.

C. Wiley, J. Kofler, M. Agha, 2020, Journal of neuropathology and experimental neurology.

Intensive Chemotherapy in Patients Aged 70 Years or Older Newly Diagnosed With Acute Myeloid Leukemia

R. Farah, A. Raptis, A. Im, 2015, Oncology research.

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

K. Foon, A. Raptis, M. Boyiadzis, 2011, Annals of Hematology.

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant

T. Owonikoko, A. Raptis, R. Balassanian, 2007, Nature Clinical Practice Oncology.

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen

M. Dew, R. Schulz, D. Posluszny, 2018, Psycho-Oncology.

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma

S. Swerdlow, D. Murray, S. Yatsenko, 2022, Diagnostic Pathology.

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Michele D. Sobolewski, Janet S. Lee, J. Mellors, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.

A. Raptis, A. Im, K. Dorritie, 2016, Leukemia research.

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

S. Jagannath, S. Lonial, N. Munshi, 2022, The New England journal of medicine.

Leukapheresis in patients newly diagnosed with acute myeloid leukemia.

D. Normolle, R. Farah, A. Raptis, 2016, Transfusion and Apheresis Science.

Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy

A. Raptis, A. Im, M. Boyiadzis, 2012, International Journal of Hematology.

Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

J. Schlesselman, K. Foon, A. Raptis, 2011, Leukemia research.

Immunohistochemistry of Inflammatory myofibroblastic tumors

Ghorbani Rostam, M. Agha, S. Khazaei, 2009 .

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, The Lancet.

SV40 small t antigen enhances the transformation activity of limiting concentrations of SV40 large T antigen

Myles A Brown, D. Livingston, X. Montano, 1987, Cell.

The t-unique coding domain is important to the transformation maintenance function of the simian virus 40 small t antigen

D. Livingston, E. Brown, H. Mamon, 1986, Molecular and cellular biology.

Thet-Unique Coding DomainIsImportant totheTransformation Maintenance Function oftheSimian Virus 40Small tAntigen

H. Mamon, M. Agha, 1986 .

A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML

M. Saul, R. Farah, A. Raptis, 2022, Leukemia and Lymphoma.

Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

M. Saul, D. Normolle, R. Farah, 2020, Oncology research.

Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation

M. Saul, R. Farah, A. Raptis, 2017, Clinical transplantation.

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

S. Jagannath, A. Jakubowiak, N. Munshi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients.

M. Wagener, Y. Doi, R. Muder, 2013, American journal of infection control.

Inferior outcome after allogeneic transplant in first remission in high‐risk AML patients who required more than two cycles of induction therapy

R. Farah, A. Raptis, A. Im, 2015, American journal of hematology.

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma

S. Swerdlow, D. Murray, S. Yatsenko, 2022, Diagnostic Pathology.

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin

J. Schlesselman, A. Raptis, M. Boyiadzis, 2009, Leukemia & lymphoma.

Intensive induction chemotherapy vs hypomethylating agent–based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia

A. Raptis, A. Im, K. Dorritie, 2018, Hematological oncology.

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

A. Wells, G. Haidar, M. Blake, 2021, Open forum infectious diseases.

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

S. Riddell, P. Greenberg, P D Greenberg, 1992, Science.

Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.

S. Swerdlow, S. Monaghan, M. Agha, 2018, The New England journal of medicine.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia

D. Normolle, R. Farah, A. Raptis, 2018, Leukemia & lymphoma.

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, Blood.

Janet S. Lee, J. Mellors, P. Bjorkman, 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse

R. Farah, A. Raptis, A. Im, 2016, Oncology research.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Hong Wang, Cliona M Rooney, Anastasios Raptis, 2017, Cytotherapy.

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

P. Sonneveld, M. Vogel, M. Delforge, 2021, Blood.

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

H. Goldschmidt, H. Einsele, M. Vogel, 2021, Blood.

PREVALENCE OF ORTHOSTATIC HYPOTENSION OR FRANK HYPOTENSION AFTER CAR-T HOSPITALIZATION

K. Dorritie, Ashish Patel, M. Agha, 2021 .

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma

S. Swerdlow, D. Murray, S. Yatsenko, 2022, Diagnostic Pathology.

Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant

R. Farah, A. Raptis, A. Im, 2016, European journal of haematology.

A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy

D. Normolle, D. Bovbjerg, R. Farah, 2021, Supportive Care in Cancer.

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

A. Wells, G. Haidar, M. Blake, 2021, medRxiv.

Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies

M. Dew, D. Posluszny, D. Bovbjerg, 2018, Supportive Care in Cancer.

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma

L. Pantanowitz, R. Farah, A. Raptis, 2016, Oncology research.

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

H. Goldschmidt, H. Einsele, M. Vogel, 2021 .

Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Blood.

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

S. Jagannath, A. Jakubowiak, P. Hari, 2021 .

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

P. Sonneveld, L. Pacaud, E. Zudaire, 2022, Blood.

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

H. Goldschmidt, S. Jagannath, P. Hari, 2021, Cancers.

Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.

H. Lazarus, M. Agha, Joseph K Franz, 2023, Blood reviews.

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, A. Lesokhin, 2023, Journal of Clinical Oncology.

Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma

S. Swerdlow, W. Shlomchik, A. Lakshman, 2019, Blood.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Hong Wang, L. Butterfield, C. Rooney, 2017, Cytotherapy.

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

M. Delforge, L. Pacaud, M. Mateos, 2021, Blood.